BTIG analyst Robert Hazlett maintained a Buy rating on Aravive (ARAV – Research Report) on March 3 and set a price target of $26.00. The company's shares closed last Friday at $1.92, close to its 52-week low of $1.82. According to TipRanks.com, Hazlett is a 3-star analyst with an average return of 3.8% and a 34.6% success rate. Hazlett covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Eiger Biopharmaceuticals, and TRACON Pharmaceuticals. Currently, the analyst consensus on Aravive is a Moderate Buy with an average price target of $20.00. See the top stocks recommended by analysts >> The company has a one-year high of $9.
https://www.tipranks.com/news/blurbs/aravive-arav-gets-a-buy-rating-from-btig?utm_source=advfn.com&utm_medium=referral
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Aravive Charts.
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Aravive Charts.